{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/04/20/3276794/0/en/Prelude-Therapeutics-Presents-Preclinical-Data-from-Development-Candidate-PRT13722-a-First-in-Class-Orally-Bioavailable-Potent-and-Highly-Selective-KAT6A-Degrader-at-American-Assoc.html", "message": "News view counter 670821 successfully enlarged"}